'Buy' Recommendation for Power3 Medical Products in New Report from Cohen Independent Research Group.

Projection of 'Strong Revenue Stream in Near-Term and Long-Term'

HOUSTON -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for breast cancer and neurodegenerative diseases, said today that a new independent research report on the company's developmental efforts and financial prospects has been completed and is now available.

The independent report by the Cohen Independent Research Group of San Rafael, California, offers a "buy" recommendation on the company, calling Power3 "well positioned to reap the benefits from its presence in the multi-billion dollar diagnostics market."

The new research report is available from Power3 (e-mail [e-mail]) and on the Cohen Research Web site (www.CohenResearch.com).

Strong IP Portfolio, Substantial Opportunity for Commercialization

In his "investment thesis and recommendation," D. Paul Cohen, founder and president of the company bearing his name, put forth a bullish outlook for Power3.

"We initiated coverage on Power3 Medical Products with a 'buy' recommendation," he said. "Power3 has leveraged its technology in the development of blood serum tests for early breast cancer detection and early diagnosis of neurodegenerative diseases, as well as for drug resistance. It has completed validation studies of more than 650 patient samples and is monitoring appropriate biomarkers for their diagnostic value. With more than 50 years of combined research expertise, Power3 has developed an intellectual property (IP) portfolio of 521 patent-pending biomarkers that offer a substantial opportunity for commercialization.

"Our research led us to the conclusion that the licensing of Power3's proprietary technology will result in a strong revenue stream in the near-term and the long-term, and we recommend Power3's for long term, risk-adverse investors," Mr. Cohen said.

Power3 'A Hidden Gem'

Mr. Cohen has extensive experience as an analyst and co-founded the West Coast offices of Bear Stearns and CBWL Hayden Stone/American Express (later Shearson Lehman Bros). He believes "there are hidden gems the investment public should be aware of . . . including Power3 Medical Products."

Steven B. Rash, chairman and CEO of Power3, said he was "delighted but not at all surprised by the independent report from Cohen Research."

"It has not been easy for Power3 to gain the attention and recognition on Wall Street and in the medical community for what we have accomplished and continue to do," Mr. Rash said. "Other companies may have sexier stories to tell, but few if any are doing work as important as the research, development and testing now on-going in our facilities."

Mr. Rash said Power3 is "moving full-speed ahead to validate and commercialize technologies we've discovered and pioneered, and to develop biomarkers and diagnostic tests that solve pressing clinical problems involving diseases that effect large populations, and which have been difficult to diagnose and treat. At Power3, we believe that early diagnosis is vital," he said, "and we are dedicated to survival and preservation of life and quality of life.

"Some cancers and neurodegenerative diseases are similar in that their early detection and treatment may allow patients to delay the onset of symptoms or retard progression thereby raising the quality of life," Mr. Rash said. "That is our goal, and progress is being made daily."

About Power3 Medical Products

Power3 Medical Products, Inc. (PWRM.PK, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases, through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.